Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › CMPX

Compass Therapeutics

CMPX Lead: Phase 2 ★ Read the deep dive → 3 Biotech Distilled articles ↓ 17 filings & releases ↓ Cash $35.5M (Jun 30, 2026) ↓ 3 verdicts ↓
Oncology Protein

Market cap $137M 180.1M shares (10-Q, Jul 28, 2026) × $0.759 close Nov 6, 2026

Most recent annual filing: 2026-03-05

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. Tovecimig Ph2 start2H 2026Tovecimig Ph2 start, 2H 2026, routine
  2. Tovecimig BLA filing4Q 2026Tovecimig BLA filing, 4Q 2026, material
  3. CTX-8371 Ph1 readout4Q 2026CTX-8371 Ph1 readout, 4Q 2026, notable
  4. CTX-10726 Ph1 readout4Q 2026CTX-10726 Ph1 readout, 4Q 2026, notable
  5. Tovecimig FDA approval2H 2027Tovecimig FDA approval, 2H 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (15 active programs)

Technology platforms

StitchMabs

Bispecific antibody discovery platform using combinatorial screening of antigen-binding domain pairs across innate and adaptive immune targets; used to identify novel bispecific antibodies for oncology applications

Capital (as filed)

Cash
$35.5M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$144M Jun 30, 2026
Operating cash flow
−$14.7M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$180M cash per the update of Sep 22, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (3)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (3 calls)

Every verdict Biotech Distilled has published on Compass Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-08-25 Watch Compass Therapeutics (CMPX) — Scientific Deep Dive for Tovecimig and the Bispecific Antibody Pipeline Strong randomized PFS signal and unmet need are offset by a pre-specified crossover-adjusted OS analysis that came back worse than unadjusted (HR 1.13), unpublished duration of response, and a balance sheet that cannot fund a commercial launch; wait for FDA meeting outcome and ESMO data before committing.
  2. 2026-09-23 Avoid UPDATE: Compass Therapeutics (CMPX) - The FDA Asked for the One Thing They Can't Afford FDA recommended a new survival trial before any BLA — the pre-named PASS condition — and the $179.9M balance sheet cannot fund a randomized OS study while also carrying a rising pre-commercial burn and three early-stage programs.
  3. 2026-10-27 Avoid UPDATE: Compass Therapeutics (CMPX) - The ESMO Receipts Came In Full COMPANION-002 dataset shows a middling 4.9-month DOR, 27.8% discontinuation rate, and a post-hoc non-significant survival adjustment (HR 0.85, p=0.53) that does not plausibly overturn the FDA's call for a survival trial this balance sheet cannot fund.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (17)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Sep 22, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)